January 18, 2018

With the rapid evolution of the global healthcare environment, medical device, diagnostics, and pharmaceutical companies must continue to navigate increasingly complex and dynamic markets.

Our team of category experts on the ground in Boston, Berlin, and Shanghai stay close to these trends and the influencers shaping them. Our expertise and evidence-based insights guide our global clients toward optimal commercialization pathways for their unique products and services.

You can find just some of these evidence-based insights below.
Boston Healthcare's Joseph V. Ferrara will join precision medicine innovators at the Precision Medicine World Congress in Silicon Valley on January 22-23, 2018.

Mr. Ferrara will join key leaders from Molecular MD, Kite Pharma, Pfizer, and others on the panel Challenges of Marrying a Drug with Diagnostics at 2:00 pm to discuss ways to create a more efficient and successful approval and commercialization process for companion diagnostics. 
The evolution of the market access function. Issues examined during the M&A process.
Vice President Robert Wenthold explored requirements for targeted market access strategies that support new medical devices in today’s cost-conscious healthcare environment at the Medtech Access Leaders Forum in Berlin in December.

You can request a copy of this presentation, and others from our website .
From January 1, 2018, Medicare uses certain private payor rate information, reported by applicable laboratories, to calculate Medicare payment rates for most laboratory tests paid under the Clinical Laboratory Fee Schedule (CLFS). Adam Crowther, Senior Associate, outlines some implications of these rate changes for diagnostics innovators. Email us to request a copy of this webinar.

Our Senior Vice President, Thomas F. Goss PharmD spoke to Lisa Jarvis from C&EN about reimbursement for novel treatments. Read his comments here .

Upcoming Events
Boston Healthcare is a global consulting firm that develops successful market access and value optimization strategies for emerging and established medical device, diagnostics and pharmaceutical companies seeking to commercialize specialized products and services that have the potential to transform standards of care and significantly improve health outcomes. We combine our multi-disciplinary consulting expertise and analytic rigor, with a deep and current understanding of evolving market and sector dynamics and trends, enabling our global clients to implement value and access strategies across their product portfolio successfully.